Tags » Daiichi Sankyo

Biosimilar Rituximab Under FDA Review

Celltrion announced June 30, 2017 that it has submitted its 351(k) application to the Food and Drug Administration for approval of its biosimilar version of rituximab. 269 more words

Daiichi Sankyo Company, Limited Product global market pipeline review: Radiant Insights, Inc

Daiichi Sankyo Company, Limited – Product Pipeline Review – 2016

Summary

Global Markets Direct’s, ‘Daiichi Sankyo Company, Limited – Product Pipeline Review – 2016’, provides an overview of the Daiichi Sankyo Company, Limited’s pharmaceutical research and development focus. 626 more words

Pharmaceuticals & Healthcare